Elicio Therapeutics received FDA feedback supporting ELI-002's Phase 3 study design; Phase 2 analysis results expected in H1 2025. Elicio Therapeutics announced positive feedback from the FDA ...
CCDC, Exscientia, and Oxford University collaborate on an automated, quantitative method for informing the design of compound selectivity across protein families Cambridge Crystallographic Data Centre ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback